Biomedical Research

Case Report - Biomedical Research (2018) Volume 29, Issue 10

A case report of successful treatment of metastatic gastral neuroendocrine carcinoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib

Li Nong and Yong-kui Lu*

Affiliated Cancer Hospital of Guangxi Medical University, PR China

*Corresponding Author:
Yong-kui Lu
Affiliated Cancer Hospital of Guangxi Medical University, PR China

Accepted on April 10, 2018 Biomed Res

DOI: 10.4066/biomedicalresearch.29-17-3677

Visit for more related articles at Biomedical Research

Abstract

Context: Neuroendocrine Tumor (NET) is arising from cells throughout the diffuse endocrine system. They comprise a broad family of tumors. Neuroendocrine Carcinoma (NEC) is a poorly differentiated and high-grade type. Advanced NEC has a poor prognosis due to a limited efficacy for chemotherapy and radiotherapy.

Case Presentation: We present here a 51-year-old Chinese woman initially diagnosed with advanced gastral neuroendocrine carcinoma. She accepted everolimus as the first line treatment, but progression after 1 month. And then she received two different cytotoxic chemotherapy regimens. Unfortunately, the treatment failed. Then, she received apatinib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens. This patient was partially responsive to apatinib with a dose of 500 mg daily. Tolerated drug-related side effects were observed.

Conclusion: Our findings indicate that some cases of neuroendocrine carcinoma may be responsive to antiangiogenic agent apatinib. Further large-scale prospective studies are needed to optimize the treatment.

Keywords

Apatinib, Gastral, Neuroendocrine carcinoma, Chemotherapy, Targeted therapy, Tyrosine kinase inhibitor, VEGFR-2.

Abbreviations

NET: Neuroendocrine Tumor; NEC: Neuroendocrine Carcinoma; ECOG: Eastern Cooperative Oncology Group; OS: Overall Survival; PFS: Progression-Free Survival; VEGFR-2: Vascular Endothelial Growth Factor Receptor-2; mTOR: Mammalian Target of Rapamycin.

Introduction

Neuroendocrine tumor is thought to arise from cells throughout the diffuse system. They comprise a broad family of tumors, Neuroendocrine Carcinoma (NEC) is a poorly differentiated and high-grade type (grade 3). The most common of which are carcinoid and pancreatic neuroendocrine tumor. An analysis of the SEER databases estimated that the incidence of neuroendocrine tumor in the United States was 5.25 cases per 100,000 people in the year 2004 [1]. Patients with neuroendocrine tumor may or may not have symptoms attributable to hormonal hyper secretion [2,3]. Standard treatment for early stage or no metastatic gastric NEC, endoscopic resection or surgical resection indicated [4]. Patients who have metastatic tumor and carcinoid syndrome should be treated with a somatostatin analog, but no clear consensus exists on the timing of octreotide initiation asymptomatic patients [5]. Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) which can use in metastatic neuroendocrine tumors [6-8]. The tumor response rate is generally low and no PFS benefit to cytotoxic chemotherapy in advanced NET [9-11]. For advanced NET, the prognosis remains very poor, even with combined, multimodal therapy. There is an urgent need for novel effective agents.

Apatinib (Hengrui Pharmaceutical Co., Ltd, Shanghai, People’s Republic of China) is a novel oral small-molecule Tyrosine Kinase Inhibitor (TKI) targeting the intracellular domain of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2). Apatinib-mediated VEGFR-2 inhibition also appears to inhibit downstream phosphorylated extracellular signal-regulated kinase [12]. Through this inhibition, Apatinib plays antiangiogenic and antitumor roles. It has shown a survival benefit in gastric cancer in a phase III trial [13] and is currently being studied in multiple tumor types including metastatic lung, colon, and breast cancer.

Here, we report a case of a 51-year-old Chinese woman with advanced gastric NEC, who received apatinib after failure of everolimus and second-line chemotherapy. The patient got a more than 11 months PFS.

Case Presentation

A 51-year-old Chinese woman diagnosed with gastral neuroendocrine carcinoma by gastroscope was referred to our hospital- Department of Chemotherapy, the cancer hospital of Guangxi medical University (Nanning, China) in August 2014 (Figure 1A). Pathology diagnosis confirmed NEC (Figure 1B) with immunophenotype: CKpan (-), Syn (+), CD56 (+), CD57 (+), S100 (+), NSE (-). Neither abdominal mass nor superficial lymph node was palpable. The patient had no fever, cough, hemoptysis and chest pain, had no carcinoid syndrome either. Chest and abdominal Computed Tomography (CT) scans demonstrated many nodules in both lungs (Figures 1C-1E).

biomedres-Gastric-endoscopy

Figure 1: Gastric endoscopy in August 2014. (A) showed mural thickening and multiple Polypoid nodules in the gastric body. Pathology of gastric biopsy. In August 2014, gastric biopsy pathology indicated gastric neuroendocrine carcinoma (B, hematoxylin and eosin, magnification 100X). Chest and abdominal Computed Tomography (CT) scans demonstrated many nodules in both lungs (C-E).

Taking into account the lung has a lot of metastatic nodules, surgery was not performed. Due to the NCCN guideline [14], we first performed the treatment with everolimus 10 mg per day. The chest CT after taking everolimus for 1 month revealed the nodules in both lungs increased. Then, the patient received 2 cycles of first-line palliative chemotherapy (etoposide 100 mg/m2 on d 1 to 3 and cisplatin 75 mg/m2 on d 1), repeated every 3 w. CT examination after the second cycle showed slight increasing of Metastatic tumors of lung, which indicated Stable Disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) [15] (Figures 2A-2C). After firstline chemotherapy, the patient was performed 2 cycles of second-line chemotherapy (irinotecan 180 mg/m2 on d 1 and raltitrexed 180 mg/m2 on d 1), repeated every 2 w. Unfortunetly, CT examination revealed Progressive Disease (PD) after two cycles chemotherapic treatments (Figures 2D-2F). The patient refused any treatment after second-line chemotherapy until January 2016, she came back to our hospital for tussiculation, CT showed the revealed an increased metastasis in both lungs. After the patient provided written, informed consent, apatinib was then administered with a dose of 500 mg/d on January 26, 2016. We evaluate the efficacy after 1 month of targeted therapy, CT showed Lung metastases were significantly reduced in size and quantity, which was considered to be a PR (Figures 3A-3F), moreover, symptoms of tussiculation reduced significantly. We continued following up the patient and check CT every 2 months, she maintained PR and No severe toxicities were observed (Table 1). The patient is considering whole brain radiotherapy due to metastases in the brain which were detected by brain MRI in November 2016 and increased in January 2017 (Figure 4). Nonetheless, she is now still undergoing the apatinib treatment on account of stable disease in Metastatic tumors of lung. A progression-free survival time of more than 11 months has been achieved.

biomedres-chemotherapy-endoscopy

Figure 2: Chest CT scans after chemotherapy. A-C. CT scans were after 2 cycles of first-line chemotherapy (etoposide 100 mg/m2 on d 1 to 3 and cisplatin 75 mg/m2 on d 1); D-F. CT scans were after 2 cycles of second-line chemotherapy (irinotecan 180 mg/m2 on d 1 and raltitrexed 180 mg/m2 on d 1). CT scans showed that the metastatic nodules became worse in size and quantity.

biomedres-metastatic-nodules

Figure 3: Chest CT scans before and after apatinib therapy. A. CT scans at different layers before apatinib therapy revealed multiple metastases in both lungs; B-F. After 1 month apatinib treatment, CT scans showed that the metastatic nodules became smaller, and then CT scans were checked in every 3 months showed the nodules in both lungs continued smaller and some of them were disappeared.

biomedres-brain-nodules

Figure 4: Metastases in the brain which were detected by brain MRI in November 2016 and increased in January 2017.

Adverse event Adverse reaction grade After treatment
Hypertension Grade II Normal value
Hand-foot syndrome Grade I Disappear
Proteinuria Grade II Disappear
Neutropenia Grade I Normal value

Table 1. Adverse events of apatinib.

Discussion

The benefits associated with cytotoxic chemotherapy in advanced NET appear to be modest, tumor response rate are generally low and no PFS benefit has been clearly demonstrated [16]. Capecitabine was used to treat advanced NET (19 cases) in a stage II study demonstrated no PR and 13 cases SD [9]. In another stage III study (E1281), which evaluated the combination of 5-FU with doxorubicin or streptozocin got a response rate of nearly 16% in both groups [10]. Everolimus, an inhibitor of mTOR is a choice to advanced NET. In a random phase III study (RADIANT-2), 429 patients were performed to two groups: group 1 (combination everolimus with octreotide) and group 2 (combination placebo with octreotide), and the everolimus group showed a PFS of 16.4 months to a PFS of 11.3 months of octreotide (P=0.026) [6]. In our case, the Chinese woman received everolimus and two lines chemotherapy, but failed.

Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2 [17]. Phases II and III studies of apatinib have shown exciting efficacy and good safety in Chinese gastric patients who have failed at least 2 chemotherapeutic regimens [13]. In the phase III study of apatinib, 5 273 patients were randomly assigned to oral apatinib group or placebo group at a ratio of 2:1. The results showed that patients receiving apatinib had significantly longer median overall survival (195 vs. 140 d; P<0.016) and longer median Progression Free Survival (PFS) (78 vs. 53 d; P<0.0001) compared with those receiving placebo. Both in the phases II and III studies of apatinib, the 3 most common adverse events were hypertension, hand-foot syndrome, and proteinuria. But there was no significant difference in severe adverse events. Several phase II clinical study was performed in other tumors, including advanced non-small cell lung cancer and advanced hepatocellular carcinoma [18], it demonstrated significantly prolonged in PFS. At present, clinical trials of apatinib include colorectal cancer, osteosarcoma and esophageal carcinoma.

Apatinib effectively inhibiting proliferation, migration and tube formation of human umbilical vein endothelial cells. Apatinib also inhibits the growth of tumors, either alone or in combination with chemotherapeutic drugs [19,20]. Importantly, cells experiment showed that apatinib can reverse Multidrug Resistance (MDR) by inhibits P-glycoprotein (ABCB1/MDR1) and ABCG2 (BCRP) which mediated transport function [21]. It also targets ABCB1-overexpressing leukemia cells HL-60, downregulates P-Erk1/2 to enhancing the efficacy of doxorubicin [22].

As for this case, the patient took apatinib after failures to everolimus and two lines chemotherapy. To our best knowledge, this is the first report of successfully using apatinib to treat advanced NET, whose best efficacy was PR, and obtained a PFS more than 11 months without severe adverse reaction. She possibly expressed MDR who could not benefit from chemotherapy, and we should check MDR before using apatinib. Are there biotical markers to pre-test the efficacy of apatinib? Is there a better prognosis in patients with high VEGFR-2 expression? We can collect tissue samples and expand the sample size of patients for VEGFR-2 mRNA detection in the future.

In conclusion, because of low side effects and improved outcomes, apatinib has demonstrated a substantial potential to be a new therapeutic option in advanced NET and a variety of tumor types.

References